{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:02:52Z","timestamp":1790053372127,"version":"4.0.1"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma (ALK\u2009+\u2009DLBCL) is a rare and highly aggressive mature B-cell lymphoma with poor responses to conventional chemotherapy and no established standard treatment. Although ALK inhibitors have shown potential activity in ALK-rearranged malignancies, their clinical utility and optimal sequencing in ALK\u2009+\u2009DLBCL remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a 41-year-old male patient diagnosed with ALK\u2009+\u2009DLBCL harboring a TFG-ALK rearrangement. The patient experienced progressive disease during the clinical course and showed rapid, although transient, responses to sequential ALK inhibitor therapy. Subsequent chemotherapy-based salvage regimens provided only limited disease control. The patient received sequential ALK-directed therapy with alectinib, ensartinib, and lorlatinib, followed by a short brigatinib rechallenge before transplantation. These ALK inhibitor-based treatments provided intermittent disease control over more than one year. After lorlatinib followed by combination chemotherapy and a short brigatinib rechallenge, the patient proceeded to hematopoietic stem cell transplantation (HSCT). However, the disease relapsed four months after transplantation, with rapid and extensive bilateral pulmonary involvement, ultimately leading to respiratory failure and death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights both the clinical utility and limitations of sequential ALK inhibitor therapy in ALK\u2009+\u2009DLBCL. A short brigatinib rechallenge was also attempted before transplantation, although its objective efficacy could not be established because of the limited treatment duration. Sequential targeted therapy may induce rapid tumor regression and help bridge patients to HSCT; however, responses are not durable, resistance can emerge rapidly, and post-transplant relapse may remain highly aggressive. More effective combination or consolidation strategies are needed to improve long-term outcomes in this rare lymphoma subtype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1932586","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:21:30Z","timestamp":1790050890000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sequential targeted therapy for anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Guocheng","family":"Zhong","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, International Cancer Center, Shenzhen Key Laboratory of Precision Medicine for Hematological Malignancies, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University Health Science Center","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, International Cancer Center, Shenzhen Key Laboratory of Precision Medicine for Hematological Malignancies, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University Health Science Center","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Tsinghua Shenzhen International Graduate School, Tsinghua University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jie","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, International Cancer Center, Shenzhen Key Laboratory of Precision Medicine for Hematological Malignancies, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University Health Science Center","place":["Shenzhen, China"]},{"name":"Tsinghua Shenzhen International Graduate School, Tsinghua University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1182\/blood.V89.5.1483","article-title":"A new subtype of large B-cell lymphoma expressing the alk kinase and lacking the 2; 5 translocation","volume":"89","author":"Delsol","year":"1997","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0178416","DOI":"10.1371\/journal.pone.0178416","article-title":"Anaplastic lymphoma kinase-positive large B-cell lymphoma: clinico-pathological study of 17 cases with review of literature","volume":"12","author":"Jiang","year":"2017","journal-title":"PLoS One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1200\/JCO.2008.21.5020","article-title":"Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis","volume":"27","author":"Laurent","year":"2009","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"529572","DOI":"10.1155\/2012\/529572","article-title":"Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma","volume":"2012","author":"Morgan","year":"2012","journal-title":"Adv Hematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1080\/10428194.2021.1941929","article-title":"Anaplastic lymphoma kinase-positive large B-cell lymphoma (alk+lbcl): a systematic review of clinicopathological features and management","volume":"62","author":"Castillo","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B7","first-page":"6977","article-title":"Promising response of anaplastic lymphoma kinase-positive large B-cell lymphoma to crizotinib salvage treatment: case report and review of literature","volume":"8","author":"Li","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1334577","DOI":"10.3389\/frhem.2024.1334577","article-title":"Case report: a patient with alk-positive large B-cell lymphoma benefited from myeloma-like treatment combined with the alk inhibitor lorlatinib","volume":"3","author":"Liu","year":"2024","journal-title":"Frontiers in Hematology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1182\/blood.2022015443","article-title":"Next-generation alk inhibitors are highly active in alk-positive large B-cell lymphoma","volume":"140","author":"Soumerai","year":"2022","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s43152-025-00061-0","article-title":"An overview of latest developments in DLBCL its pathogenesis, immune significance, prognosis and targets","volume":"6","author":"Sarode","year":"2025","journal-title":"Current Tissue Microenvironment Reports"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1038\/s41588-023-01561-1","article-title":"Noncoding mutations cause super-enhancer retargeting resulting in protein synthesis dysregulation during B cell lymphoma progression","volume":"55","author":"Leeman-Neill","year":"2023","journal-title":"Nat Genet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.1158\/1078-0432.CCR-14-1511","article-title":"Two novel alk mutations mediate acquired resistance to the next-generation alk inhibitor alectinib","volume":"20","author":"Katayama","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12957-023-02935-9","article-title":"First case report of ensartinib in a patient with metastatic alk rearranged lung cancer with alk I1171n mutation: a case report","volume":"21","author":"Yang","year":"2023","journal-title":"World J Surg Oncol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1932586\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:21:31Z","timestamp":1790050891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1932586\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":13,"alternative-id":["10.3389\/fmed.2026.1932586"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1932586","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1932586"}}